ClinicalTrials.gg
CompletedNCT05360927Updated May 4, 2022

Safety and Tolerability of BDB-001 Injection in Healthy Subjects

A Phase 1 interventional study of BDB-001 injection and Placebo in Healthy, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-04.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Sep 2019, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A clinical study to evaluate the safety,tolerability,PK and PD characteristics of BDB-001 Injection in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 but ≤ 65, male and female;
  • Medical histories, physical examinations, laboratory examinations and study-related examinations and tests of the subjects,the Investigator judges that they are healthy;
  • Body weight: 50- 80 kg, inclusive; : 18.0 -26.0 kg/m2, inclusive;
  • Vital signs: Blood pressure (90 mmHg≤ systolic ≤140 mmHg, 50 mmHg≤ diastolic ≤90 mmHg), heart rate (50≤ heart rate ≤100 beats/min), body temperature \< 37°C;
  • Subjects (including their partners) agree to take highly effective measures during the study, and they have no birth plan or sperm donation plan within 6 months after the end of the study;
  • Subjects are aware of the risks of the study, and voluntarily participate in the clinical study and sign an form (ICF).

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgment of the Investigator might put the subject as risk on this study;
  • Past history of tuberculosis, history of contact with active tuberculosis, TB-SPOT test results exceeding the upper limit of 2 times or more, and recent infectious diseases;
  • During the screening and baseline period, the white blood cell count and C-reactive protein test results are abnormal and have clinical significance, : male \<120g/L or female \<110g/L;
  • (ECG) abnormalities and have clinical significance;
  • Subjects who have an disease or an immune deficiency disease, or a family history of an autoimmune disease or an immune deficiency disease;
  • Subjects with clinically obvious allergic diseases;
  • Positive screening test results for (HIV-1/HIV-2) antibodies, surface antigen (HBsAg) or antibody (HCV-Ab), treponema pallidum antibody;
  • Participate in any drug or vaccine clinical trial as a subject within 3 months before screening or prepare to be vaccinated during the study period to 2 months after the end of the study;
  • Have received any monoclonal antibody or biological agent treatment within the previous 3 months;
  • Have taken drugs that may affect immune function within 6 months before screening or have taken prescription/over-the-counter drugs within the previous 14 days;
  • Subjects who have donated either more than approximately 500 mL of blood within 3 months prior to screening or any plasma within 4 weeks prior to screening; Subjects who donated blood (>400 ml) within 3 months prior to screening, or plasma exchange within 4 weeks prior to screening;
  • Drink more than 5 cups of coffee, tea or cola per day (150ml and above per cup);
  • Subjects who test positive for alcohol or drugs during the screening;
  • Subjects who smoke or smoke test results are positive;
  • Subjects with poor compliance;
  • Pregnant or lactating women;
  • The investigator believes that there are any subjects who are not suitable to participate in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Cohort 0.3mg/kg

    All participants (fasted) received either 0.3 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 1mg/kg

    All participants (fasted) received either 1 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 3mg/kg

    All participants (fasted) received either 3 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 8mg/kg

    All participants (fasted) received either 8 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 16mg/kg

    All participants (fasted) received either 16 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

  • Experimental
    Cohort 20mg/kg

    All participants (fasted) received either 20 mg/kg of BDB-001 as a single dose or dose-matched placebo.

    Drug: BDB-001 injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities

    Time frame: Up to 50 days

  2. Maximum plasma concentration (Cmax)

    Time frame: Up to 1200 hours postdose

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC0inf)

    Time frame: Up to 1200 hours postdose

  4. Area under the plasma concentration-time curve from time 0 to 1200hr(AUC00-1200hr)

    Time frame: Up to 1200 hours postdose

  5. Time of maximum concentration (Tmax)

    Time frame: Up to 1200 hours postdose

  6. Elimination half-life (t1/2)

    Time frame: Up to 1200 hours postdose

  7. Clearance (CL)

    Time frame: Up to 1200 hours postdose

  8. Apparent volume of distribution (Vz)

    Time frame: Up to 1200 hours postdose

  9. Mean residence time (MRT)

    Time frame: Up to 1200 hours postdose

Secondary outcomes

  1. Number of participants developing anti-BDB-001 antibodies

    Time frame: Up to 50 days

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2020, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 4, 2022
StartActual
Sep 25, 2019
Primary completionActual
Dec 25, 2020
CompletionActual
Dec 25, 2020
Last update
May 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05360927
Collaborators
Beijing Defengrei Biotechnology Co.,Ltd
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Sep 25, 2019
Primary completion
Dec 25, 2020
Completion
Dec 25, 2020
Last update
May 4, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion